FDA Updates Darunavir Tablet and Oral Suspension Labeling with Pediatric Dosing Information
“On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Darunavir (Prezista) patient drug summary
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Department of Health | Health | HIV AIDS | Infectious Diseases | Pediatrics | Prezista | Websites